Alnylam Pharmaceuticals Inc (ALNY)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Alnylam Pharmaceuticals Inc (ALNY) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011496
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiovascular and metabolic disease; and hepatic infectious disease. It also offers Alnylam 5×15 program for advancing genetically defined disease targets for the treatment of respiratory syncytial virus and liver cancer. Alnylam employs lipid nanoparticles for intravenous systemic delivery of sRNAi to right body organs and cells so that it could trigger the RNAi mechanism. The company works in partnership with Merck, Medtronic, Roche, Novartis, Biogen, Takeda, Cubist, GlaxoSmithKline, Ascletis, The Medicines Company, Kyowa Hakko Kirin, Monsanto, and Sanofi Genzyme for advancing its RNAi therapeutics. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc (ALNY) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Alnylam Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Alnylam Pharmaceuticals Inc, Medical Equipment, Deal Details 10
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 10
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 11
Equity Offering 12
Alnylam Pharma Raises USD805 Million in Public Offering of Shares 12
Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 14
Alnylam Pharma Raises USD518 Million in Public Offering of Shares 16
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 18
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 19
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 20
Alnylam Pharmaceuticals Inc – Key Competitors 22
Alnylam Pharmaceuticals Inc – Key Employees 23
Alnylam Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Joint Venture 26
Recent Developments 27
Strategy And Business Planning 27
Sep 20, 2016: Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK 27
Financial Announcements 28
Aug 09, 2017: Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity 28
May 05, 2017: Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity 30
Feb 08, 2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity 32
Nov 02, 2016: Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity 35
Aug 04, 2016: Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress 38
May 02, 2016: Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress 41
Feb 11, 2016: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress 44
Corporate Communications 48
May 09, 2017: Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders 48
Jan 03, 2017: Alnylam Announces Management Change and Key Promotion 50
Sep 19, 2016: Alnylam Expands and Strengthens Management Team as it Plans for Commercialization 51
Legal and Regulatory 52
Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 52
Product News 53
Jun 12, 2017: Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Alnylam Pharmaceuticals Inc, Medical Equipment, Key Facts, 2016 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Alnylam Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Alnylam Pharmaceuticals Inc, Deals By Market, 2011 to YTD 2017 8
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 10
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 11
Alnylam Pharma Raises USD805 Million in Public Offering of Shares 12
Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 14
Alnylam Pharma Raises USD518 Million in Public Offering of Shares 16
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 18
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 19
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 20
Alnylam Pharmaceuticals Inc, Key Competitors 22
Alnylam Pharmaceuticals Inc, Key Employees 23
Alnylam Pharmaceuticals Inc, Subsidiaries 25
Alnylam Pharmaceuticals Inc, Joint Venture 26

★海外企業調査レポート[Alnylam Pharmaceuticals Inc (ALNY)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Biotest AG (BIO):企業の財務・戦略的SWOT分析
    Biotest AG (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • LinkedIn Corp:企業の戦略的SWOT分析
    LinkedIn Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Trina Solar Ltd-エネルギー分野:企業M&A・提携分析
    Summary Trina Solar Ltd (Trina Solar) is a vertically-integrated solar power products manufacturer. The company manufactures a wide variety of PV modules, both monocrystalline and multicrystalline; ingots, wafers, cells and solar modules. The company also designs, constructs, sells and operates sola …
  • Spark Infrastructure Group:発電所・企業SWOT分析
    Spark Infrastructure Group - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • Bioaster-製薬・医療分野:企業M&A・提携分析
    Summary Bioaster is a technology research institute that conducts research on infectious diseases and microbiology. The institute offers services in the therapeutic areas of respiratory diseases, diarrhea, AIDS and tuberculosis. Its technologies include biological sample collections, genomics and tr …
  • Glanbia Nutritionals Inc:企業の戦略的SWOT分析
    Glanbia Nutritionals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Watt’s S.A.:企業の戦略・SWOT・財務情報
    Watt's S.A. - Strategy, SWOT and Corporate Finance Report Summary Watt's S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Teijin Limited:企業の戦略・SWOT・財務分析
    Teijin Limited - Strategy, SWOT and Corporate Finance Report Summary Teijin Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Dermalogica Inc:企業の戦略・SWOT・財務情報
    Dermalogica Inc - Strategy, SWOT and Corporate Finance Report Summary Dermalogica Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Westlake Chemical Corporation:企業の戦略・SWOT・財務情報
    Westlake Chemical Corporation - Strategy, SWOT and Corporate Finance Report Summary Westlake Chemical Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Star Gas Partners L.P.:企業の戦略・SWOT・財務情報
    Star Gas Partners L.P. - Strategy, SWOT and Corporate Finance Report Summary Star Gas Partners L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Firalis SAS:企業の製品パイプライン分析2018
    Summary Firalis SAS (Firalis) is a biotechnology company that develops biomarkers and biomarker-based diagnostic kits. The company’s biomarker products comprise recombinant proteins and calibrants, Elisa kits, and monoclonal antibodies, among others. It offers biomarker services such as flow cytomet …
  • Octapharma AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Octapharma AG (Octapharma) is a human protein manufacturer that focuses on developing and producing human proteins from human plasma and cell lines. The company treats patients worldwide with products across immunotherapy (immune disorders), haematology (coagulation disorders), and critical …
  • Nedbank Group Ltd (NED):企業の財務・戦略的SWOT分析
    Nedbank Group Ltd (NED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Enel SpA:企業の戦略・SWOT・財務情報
    Enel SpA - Strategy, SWOT and Corporate Finance Report Summary Enel SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Amazon.com Inc (AMZN):企業の財務・戦略的SWOT分析
    Amazon.com Inc (AMZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Stereotaxis Inc (STXS):企業の財務・戦略的SWOT分析
    Stereotaxis Inc (STXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Powerco Ltd:企業の戦略的SWOT分析
    Powerco Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Bio-Path Holdings Inc (BPTH):医療機器:M&Aディール及び事業提携情報
    Summary Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) …
  • Hisamitsu Pharmaceutical Co Inc (4530):製薬・医療:M&Aディール及び事業提携情報
    Summary Hisamitsu Pharmaceutical Co Inc (Hisamitsu Pharmaceutical) is a pharmaceutical company that provides pain management products. The company manufactures and sells pain relieving products, dermatological products, and quasi drugs, among others. Hisamitsu Pharmaceutical provides its products in …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆